# Theravance Biopharma clinical trials: 47 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials with Theravance Biopharma as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Theravance Biopharma: 47 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/theravance-biopharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 25, 2023 | NCT05696717 | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | Theravance Biopharma | Phase 3 | Active not recruiting | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05696717) |
| December 21, 2021 | NCT05165485 | Phase 4 COPD and Suboptimal Inspiratory Flow Rate | Theravance Biopharma | Phase 4 | Completed | Chronic Obstructive Pulmonary Disease | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05165485) |
| October 25, 2021 | NCT05091723 | TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation | Theravance Biopharma | Phase 1 | Completed | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05091723) |
| December 30, 2020 | NCT04688632 | Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects | Theravance Biopharma | Phase 1 | Completed | Symptomatic Neurogenic Orthostatic Hypertension, nOH | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04688632) |
| December 23, 2020 | NCT04681079 | Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 | Theravance Biopharma | Observational | Completed | COVID-19 | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04681079) |
| October 19, 2020 | NCT04589260 | TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis | Theravance Biopharma | Phase 1 | Terminated | Idiopathic Pulmonary Fibrosis (IPF) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04589260) |
| October 14, 2020 | NCT04587713 | Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects | Theravance Biopharma | Phase 1 | Completed | Intestinal Disorder, Bowel Diseases, Inflammatory | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04587713) |
| May 27, 2020 | NCT04402866 | TD-0903 for ALI Associated With COVID-19 | Theravance Biopharma | Phase 2 | Completed | Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04402866) |
| April 17, 2020 | NCT04350736 | First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 | Theravance Biopharma | Phase 1 | Completed | Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19 | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04350736) |
| December 16, 2019 | NCT04200573 | Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 | Theravance Biopharma | Phase 1 | Completed | Symptomatic Neurogenic Orthostatic Hypertension, nOH | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04200573) |
| November 4, 2019 | NCT04150341 | Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response | Theravance Biopharma | Phase 2 | Completed | Asthma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04150341) |
| September 19, 2019 | NCT04095793 | Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Theravance Biopharma | Phase 3 | Terminated | Symptomatic Neurogenic Orthostatic Hypotension | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04095793) |
| August 5, 2019 | NCT04044339 | Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects | Theravance Biopharma | Phase 1 | Completed | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04044339) |
| April 18, 2019 | NCT03920254 | TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study | Theravance Biopharma | Phase 2/3 | Terminated | Ulcerative Colitis (UC) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03920254) |
| February 4, 2019 | NCT03829657 | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Theravance Biopharma | Phase 3 | Terminated | Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF) | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03829657) |
| November 29, 2018 | NCT03758443 | Efficacy & Safety of TD-1473 in Ulcerative Colitis | Theravance Biopharma | Phase 2/3 | Terminated | Ulcerative Colitis (UC) | 239 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03758443) |
| November 23, 2018 | NCT03750565 | Multiple Dose Ethnobridging PK Study in Healthy Subjects | Theravance Biopharma | Phase 1 | Completed | Inflammatory Bowel Diseases, IBD | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03750565) |
| November 23, 2018 | NCT03750552 | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Theravance Biopharma | Phase 3 | Completed | Symptomatic Neurogenic Orthostatic Hypotension | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03750552) |
| August 29, 2018 | NCT03652038 | Single and Multiple Ascending Dose Study of TD-8236 by Inhalation | Theravance Biopharma | Phase 1 | Completed | Asthma | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03652038) |
| August 17, 2018 | NCT03635112 | Efficacy and Safety of TD-1473 in Crohn's Disease | Theravance Biopharma | Phase 2 | Terminated | Crohn's Disease | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03635112) |
| June 13, 2018 | NCT03555617 | Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study | Theravance Biopharma | Phase 1 | Completed | Inflammatory Bowel Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03555617) |
| February 14, 2018 | NCT03432793 | Drug-Drug Interaction (DDI) Study for TD-9855 | Theravance Biopharma | Phase 1 | Completed | Drug Drug Interaction (DDI) | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03432793) |
| January 24, 2018 | NCT03408470 | TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects | Theravance Biopharma | Phase 1 | Completed | Intestinal Disorders, Bowel Diseases, Inflammatory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03408470) |
| April 6, 2017 | NCT03103412 | TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) | Theravance Biopharma | Phase 1 | Completed | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03103412) |
| November 3, 2016 | NCT02954263 | Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects | Theravance Biopharma | Phase 1 | Completed | Healthy Adults, Elderly Subjects | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02954263) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 2 | 10 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 39 |
| Terminated | 7 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Inflammatory Bowel Diseases | 7 |
| Pulmonary Disease, Chronic Obstructive | 6 |
| COVID-19 | 4 |
| Pure Autonomic Failure | 4 |
| Parkinson Disease | 4 |
| Acute Lung Injury | 3 |
| Asthma | 3 |
| Colitis, Ulcerative | 3 |
| Hypotension, Orthostatic | 3 |
| Hypotension | 3 |
| Dizziness | 3 |
| Syncope | 3 |
| Hepatitis C | 2 |
| Infections | 2 |
| Bacterial Infections | 2 |
| Intestinal Diseases | 2 |
| Attention Deficit Disorder with Hyperactivity | 2 |
| Multiple System Atrophy | 2 |
| Fibromyalgia | 2 |
| Parkinsonian Disorders | 2 |
| Gastroparesis | 2 |
| Shy-Drager Syndrome | 1 |
| Pneumonia | 1 |
| Idiopathic Pulmonary Fibrosis | 1 |
| Pulmonary Fibrosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spanish restaurants in the United States](https://specstream.ai/data/businesses/spanish-restaurants/united-states)
- [Seafood wholesalers in the United States](https://specstream.ai/data/businesses/seafood-wholesalers/united-states)
- [Remodeling contractors in the United States](https://specstream.ai/data/businesses/remodeling-contractors/united-states)
- [Prosthodontics practices in the United States](https://specstream.ai/data/businesses/prosthodontics-practices/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
- [Pediatric nephrology practices in the United States](https://specstream.ai/data/businesses/pediatric-nephrology-practices/united-states)
